Intravesical instillation with live, attenuated Mycobacterium Bacillus Calmette-Guérin (BCG) is an effective therapy for bladder cancer. Two recent analyses provide new insight into the clinical efficacy of BCG versus chemotherapy with mitomycin C in intermediate-risk and high-risk bladder cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
“First do no harm” and the importance of prediction in oncology
EPMA Journal Open Access 17 July 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303–314 (2008).
Persad, R. A. et al. Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations. Eur. Urol. 7 (Suppl.), 637–650 (2008).
Huncharek, M., McGarry, R. & Kupelnick, B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 21, 765–770 (2001).
Sylvester, R. J. Bacillus Calmette-Guerin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues. Eur. Urol. 56, 266–268 (2009).
Dalbagni, G. Is intravesical Bacillus Calmette-Guerin better than mitomycin for intermediate-risk bladder cancer? Eur. Urol. 56, 257–258 (2009).
Jarvinen, R., Kaasinen, E., Sankila, A. & Rintala, E. Long-term efficacy of maintenance Bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur. Urol. 56, 260–265 (2009).
Malmström, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247–256 (2009).
Böhle, A., Jocham, D. & Bock, P. R. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169, 90–95 (2003).
Böhle, A. & Bock, P. R. Intravesical Bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63, 682–686 (2004).
Sylvester, R. J., van der Meijden, A. P. M. & Lamm, D. L. Intravesical Bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964–1970 (2002).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Böhle, A. Meta-analysis of BCG versus mitomycin C—a deeper insight?. Nat Rev Urol 7, 8–10 (2010). https://doi.org/10.1038/nrurol.2009.253
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.253
This article is cited by
-
“First do no harm” and the importance of prediction in oncology
EPMA Journal (2010)
